Assistant Professor of Medicine, Johns Hopkins University School of Medicine
Internal Medicine
Dr. Kelly E. Dooley, MD
|
|
Give Review
Kelly E. Dooley, MD is an expert in the field of Internal Medicine. She graduated from Duke University School of Medicine. Duke University School of Medicine is one of the top medical schools in the US. Duke University School of Medicine is ranked 8/29 in Research/PrimaryCare. Kelly E. Dooley, MD is a published doctor. She has 28 papers published. The most current publication "Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug." Kelly E. Dooley, MD is registered with Medicare and accepts Medicare payments.
Publications
- Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.
- Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
- Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.
- Quantification of Rifapentine, a Potent Anti-Tuberculosis Drug, from Dried Blood Spot Samples Using Liquid Chromatographic-Tandem Mass Spectrometric Analysis.
- Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.
- Pipeline of drugs for related diseases: tuberculosis.
- World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?
- Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase...
- Qualitative study of perceived causes of tuberculosis treatment default among health care workers in Morocco.
- Old Drugs, New Purpose: Retooling Existing Drugs for Optimized Treatment of Resistant Tuberculosis.
- TB and HIV Therapeutics: Pharmacology Research Priorities.
- Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Gro...
- Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
- Tuberculosis and diabetes mellitus: convergence of two epidemics.
- Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis.
- Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries.
- Treatment of latent tuberculosis infection: challenges and prospects.
- Fluoroquinolone resistance in patients with newly diagnosed tuberculosis.
- Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis.
- A 39-year-old man with hip pain and respiratory failure.
- Treatment Default amongst Patients with Tuberculosis in Urban Morocco: Predicting and Explaining Default and Post-Default Sputum Smear and Drug Susceptibility Results.
- Seroprevalence of hepatitis B and C among barbers and their clients in the Rabat region of Morocco.
- Herbal remedies in resource-poor settings: friend or foe?
- T-SPOT.TB responses during treatment of pulmonary tuberculosis.
- Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
- TMC207: the first compound of a new class of potent anti-tuberculosis drugs.
- Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco.
Schools
Duke University
Johns Hopkins University SchMed
Doctors Specialties
- Infectious Disease Medicine
- Internal Medicine
Accepted Insurances
Education
-
Johns Hopkins University -
Duke University School of Medicine
Hospital
-
Johns Hopkins Bayview Medical Center -
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1568508489 | |
| NPPES Provider LastName | DOOLEY | |
| NPPES Provider FirstName | KELLY | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 215.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1568508489 |
| Last Name Of The Provider | DOOLEY |
| First Name Of The Provider | KELLY |
| View All |
Similar Doctors
|
|
Dr. Amber E. Johnson, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Debra E. Khani, MD |
|
|
Dr. Nan Ni, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer S. Huson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard Palladino, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Damani A. Piggott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allison L. Agwu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard W. Larue Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maryana Shenderov, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel A. Wolde-Rufael, MD
This Doctor is OpenDoctor Recommended.
|